Our new report will show you how the Chinese pharma market will develop from 2010. You can identify where the greatest opportunities will lie. You can have our report today, staying ahead.

We provide forecasts for the main therapeutic areas in the Chinese prescription drug market, as well as giving coverage of OTC medicines. You will find revenues for generic and original-branded medicines from 2009 to 2025. Our report also discusses companies in the sector - domestic and foreign - assessing their prospects.

How will China's market restraints affect pharma growth? And which companies are best placed to harness the opportunities there? How will trends in disease and healthcare shape the industry and market from 2010 onwards?

We analyse strengths, weaknesses and revenue trends of the Chinese pharma sector. Our report shows you trends to watch out for. Novel and generic drug producers can benefit. Developments will occur for small-molecule agents and biotech drugs.

Our new report also covers China's healthcare policy - we discuss healthcare legislation and its potential effects on the industry and market. We also cover prospects for foreign investment in the Chinese pharma sector.

Our analyses show that the Chinese pharma market will still experience growth rates above those of any developed market over coming years. But where will its revenue growth be concentrated, and why? We show how you could benefit there, letting you assess China's potential now.

Analysis of the Chinese pharma sector to meet your needs

Our study harnesses primary and secondary research to meet your needs. We provide revenue forecasts, market share analyses, sector developments and other data. You can assess commercial strengths, weaknesses, opportunities and threats. We include 35 tables and figures and two expert interviews (shown in the accompanying lists).


Report Highlights
Companies Listed
Abbott Laboratories
Agilent
Alliance Boots
American California Pharmaceutical Group
American Heart Association
Anhui BBCA Biochemical
Apotex
AppTec Laboratory Services
Asahi Chemical
ASKA Pharmaceutical
AstraZeneca
Baxter International
Bayer Schering Pharma
Beijing Bio-Ekon Biotechnology Co.
Beijing Economic and Technological Development Area
Beijing GP Medical Technologies
Beijing Yuande Bio-Medical Engineering Co.
BGI (formerly Beijing Genomics Institute)
Bio-Bridge Science
Biofarm
BMJ (British Medical Journal)
BMP China
BMP Sunstone Corporation
Bracco Group
Bristol-Myers Squibb
Charles River Laboratories
ChemPartner
Chengdu Institute of Biological Products
China Academy of Science
China Chain Stores and Franchise Association (CCSFA)
China Council for International Investment Promotion (CCIIP)
China Medical Technologies
China National Biotec Group (CNBG)
China National Corporation of Medicines
China National Group Corporation of Traditional & Herbal Medicine
China National Immunization Program
China National Medical Equipment Industry Corporation
China National Pharmaceutical Foreign Trade Corporation
China National Pharmaceutical Group Corporation (Sinopharm)
China National Pharmaceutical Industry Corporation
China Nepstar Chain Drugstore (Nepstar)
China Ostuka Pharmaceutical Co.
China Pharma Holdings
China Pharmaceutical Advertising Company
China Pharmaceutical Exhibition Corporation
China Pharmaceutical Group Co. (China Pharma)
China Securities Regulatory Commission
China Sky One Medical
Chinese Academy of Sciences
Chinese Diabetes Society
Claris Lifesciences
CMED Technologies
CSPC Pharmaceutical Group Limited (CSPC Pharma)
Egret Pharma (Shanghai)
Eli Lilly and Company
Enhance BioMedical Holdings (Shanghai)
Enhance Holding Corp
European Medicines Agency (EMA/EMEA)
Food and Drug Administration (US FDA)
Gedeon Richter
Genentech
GlaxoSmithKline (GSK)
Goldman Sachs
Guangzhou Medical University
Guangzhou Pharmaceutical Company
Guangzhou Pharmaceuticals Corporation
Guilin Sanjin Pharmaceutical Co.
Harbin First Bio-Engineering Company
Harbin Medical University
Harbin Pharmaceutical Group Co.
Harbin Pharmaceutical Group Holding Company
Harbin Tian Di Ren Medical Science and Technology Company
HB Minkang
HB.SJZ.Shenwei
HD Biosciences
Hebei Pharmaceutical Group
Heilongjiang Haina Pharmaceutical
Heilongjiang Tianlong Pharmaceutical
HN Tongyongsany ANG
Hualan Biological Engineering
Hutchison MediPharma
Il Yang
International Federation of Pharmaceutical Manufacturers Associations (IFPMA)
Jilin University
Johnson & Johnson (J&J)
Leti
Livzon
LN. JZ Aohong
Medicilon
Merck & Co.
Millennium Pharmaceuticals
Mindray Medical International
Ministry of Health (China)
National Center for Drug Screening (NCDS)
National Food and Drug Administration
National Medicine Administration
National Reform and Development Commission (NRDC)
Nature
NeoStem
New England Journal of Medicine
New York Stock Exchange
North East Agricultural University
Northeast General Pharmaceutical
Novartis
NovaSector
Novo Nordisk
Nycomed Pharma
Orexo
Path Pharma
Peking University
Peng Lai Jin Chuang Pharmaceutical Company
Pfizer
Psyma Business Research China
Qingdao Huazhong Pharmaceutical Co.
R&D-based Pharmaceutical Association Committee (RDPAC)
Roche
Rottapharm
Sanjing Pharmaceutical Co.
Sanofi Pasteur
Sanofi-Aventis
Schwabe Pharmaceuticals
Shang Pharm
Shanghai Administration for Industry and Commerce
Shanghai Hengrui Pharmaceuticals Co.
Shanghai Institute of Materia Medica
Shanghai Jiao Tong University
Shanghai Municipal Food and Drug Administration
Shanghai Stock Exchange
Shenyang Sunshine Pharmaceutical Company Limited (Sunshine)
Shenzhen Neptunus Interlong Bio-Technique Co.
Shijiazhuang No. 4
Shijiazhuang Pharmaceutical Group
Sichuan Industrial Institute of Antibiotics
Sino-American Shanghai Squibb Pharmaceutical
Sinopharm Medicine Holding Co.
Sinopharm United Engineering Company
Sino-Swed Pharmaceutical Corp.
Sinovac Biotech (Beijing Kexing Bioproducts)
Special Program for Research and Training in Tropical Diseases (WHO-affiliated)
State Food and Drug Administration (SFDA)
State Industrial Property Office (SIPO)
State Key Lab of Respiratory Disease
Sucampo Pharmaceuticals
Sundia Meditech
Sunstone Pharmaceuticals Co.
Suzhou Erye Pharmaceuticals Company
Suzhou Capsule Co.
Takeda Pharmaceutical Company
The Ministry of Labor and Social Security (MOLSS)
Thermo Fisher Scientific
Tianyin Pharmaceutical Co.
Tsinghua University
Tufts Center for the Study of Drug Development (Tufts CSDD)
United Pharmatech
Weisheng Pharmaceutical (Shijiazhuang) Co.
Working Group on Obesity in China
World Bank
World Health Organization (WHO)
World Trade Organization (WTO)
WuXi AppTec
WuXi PharmaTech
Xian-Janseen Pharmaceutical
Yuhan Corporation
Zhangjiang Group
Zhangjiang Hi-Tech Park
Zhejiang Medicine
Zhognuo
Zhongrun
Zhongrun Neimeng
[Studien Infos ausblenden]

1. Executive Summary
1.1 China Pharmaceutical Market Review
1.2 Summary of Report Contents
1.3 Research and Analysis Methods

2. Chinese Pharmaceutical Market Overview
2.1 The Chinese Market Forecast 2010-2025
2.2 The Origins of China's Pharmaceutical Growth
2.3 Healthcare Reform
2.3.1 Healthy China 2020: Hopes and Challenges
2.4 Pricing Policies
2.4.1 Pricing Policies for Subsidised Drugs
2.5 Intellectual Property Protection in China
2.6 The Disease Burden in China
2.6.1 Cerebrovascular and Cardiovascular Conditions
2.6.2 COPD
2.6.3 Cancer
2.6.4 Diabetes
2.6.5 Other Diseases

3. Breakdown of the Chinese Market 2010-2025
3.1 The Chinese Pharmaceutical Market Generated over $60bn in 2009
3.2 The Chinese Market - How Much Growth Possible This Decade?
3.3 The Original-Branded Drug Market Will Grow Faster than the Generics Market?
3.4 OTC Drugs versus Prescription Drugs
3.5 Medical Devices and Other Sectors
3.6 China as a Pharmaceutical Hub

4. Prescription Pharmaceutical Market Forecasts 2010-2025
4.1 China: Prescription Market 2010-2025
4.2 Antibiotics and Anti-infectives Market 2010-2025
4.3 Traditional Chinese Medicines (TCM) 2010-2025
4.3.1 Western Medicine and TCM: Complementary or Competitors?
4.3.2 Forecast for TCM 2010-2025
4.4 Vasotherapeutics Market 2010-2025
4.4.1 Forecast for Vasotherapeutics Market 2010-2025
4.5 Solutions Market 2010-2025
4.5.1 Forecast for Solutions Market 2010-2025
4.6 Antiulcerants Market 2010-2025
4.6.1 Forecast for Antiulcerants Market 2010-2025
4.7 Immunostimulating Agents Market 2010-2025
4.7.1 Forecast for Immunostimulating Agents Market 2010-2025
4.8 Diabetes Treatments Market 2010-2025
4.8.1 Forecast for Diabetes Treatments Market 2010-2025
4.9 Vaccines Market 2010-2025
4.9.1 Forecast for Vaccines Market 2010-2025

5. The Chinese OTC Market 2010-2025
5.1 The OTC Market: Prospects for Revenue Growth
5.2 Drivers of the OTC Market
5.3 Leading Products and Companies in the Market

6. Other Areas of China's Pharmaceutical Sector
6.1 Clinical Trials
6.1.1 Advantages and Disadvantages of China as a Destination
6.1.2 Forecast for China's Clinical Trials Market 2010-2025.
6.2 Active Pharmaceutical Ingredients (APIs)
6.2.1 Forecast for Active Pharmaceutical Ingredients (APIs) 2010-2025

7. Key Players in the Chinese Pharma Market
7.1 Bayer
7.2 AstraZeneca
7.3 Sanofi-Aventis
7.4 Pfizer
7.5 Roche
7.6 GlaxoSmithKline
7.7 Merck & Co.
7.8 Novo Nordisk: Producing Insulin in China
7.9 Selected Domestic Companies
7.10 Sinovac Biotech (Beijing Kexing Bioproducts)
7.11 WuXi AppTec
7.12 Mindray Medical International
7.13 China Nepstar Chain Drugstore
7.14 Hualan Biological Engineering (Hualan)
7.15 Tianyin Pharmaceutical Co.
7.16 Guangzhou Pharmaceuticals Corporation/ Guangzhou Pharmaceutical Company
7.17 China Sky One Medical
7.18 Harbin Pharmaceutical Group Holding Company
7.19 CSPC Pharmaceutical Group Limited (CSPC Pharma)
7.20 China Medical Technologies
7.21 China National Biotec Group (CNBG)
7.22 China National Pharmaceutical Corporation (Sinopharm)

8. The Chinese Pharma Market: SWOT Analysis
8.1 Strength in Size
8.2 Longstanding Structural Weaknesses
8.3 Opportunities in the Domestic Market and Abroad
8.4 Internal Threats

9. Expert Opinions
9.1 Interview with Jean-Francois Tremblay, Chemical & Engineering News
9.1.1 The Appeal of China to Big Pharma
9.1.2 The Human Resources of China's CROs
9.1.3 Other Logistical Requirements of China's CROs
9.1.4 CROs and Drug Approval Rates
9.1.5 China's Domestic R&D
9.1.6 The Importance of China's Returnees
9.2 Interview with an Anonymous Expert on the Chinese Pharma Sector
9.2.1 The Potential of the Chinese Market
9.2.2 The Importance of Generics
9.2.3 The Outsourcing of Pharma Operations
9.2.4 The IP Issue
9.2.5 China's API Export Market

10. Conclusions
10.1 China's Market Potential from 2010
10.2 The Fastest-Growing Sector
10.3 China Will Become an Increasingly-Important Pharmaceutical Hub
10.4 China Faces Challenges, But Will Become a Dominant Pharma Market
[Inhaltsverzeichnis ausblenden]

Table 2.1 The Chinese Pharmaceutical Market: Revenues ($bn), Growth (%), CAGR (%), 2009-2025
Table 3.1 The Chinese Pharmaceutical Market by Sector: Revenues ($bn), Growth (%), CAGR (%), 2009-2025
Table 3.2 Medical Equipment Market: Revenues ($bn), Growth (%), CAGR (%), 2009-2025
Table 4.1 Prescription Drug Market: Revenues ($bn), Growth (%), CAGR (%), 2009-2025
Table 4.2 Antibiotics Market: Revenues ($bn), Growth (%), CAGR (%), 2009-2025
Table 4.3 TCM Market: Revenues ($bn), Growth (%), CAGR (%), 2009-2025
Table 4.4 Vasotherapeutics: Revenues ($bn), Growth (%), CAGR (%), 2009-2025
Table 4.5 Solutions: Revenues ($bn), Growth (%), CAGR (%), 2009-2025
Table 4.6 Antiulcerants: Revenues ($bn), Growth (%), CAGR (%), 2009-2025
Table 4.7 Immunostimulating Agents: Revenues ($bn), Growth (%), CAGR (%), 2009-2025
Table 4.8 Diabetes Treatments: Revenues ($bn), Growth (%), CAGR (%), 2009-2025
Table 4.9 Vaccines: Revenues ($bn), Growth (%), CAGR (%), 2009-2025
Table 5.1 OTC Market: Revenues ($bn), Growth (%), CAGR (%), 2009-2025
Table 6.1 Clinical Trials Market: Revenues ($bn), Growth (%), CAGR (%), 2009-2025
Table 6.2 API Export Market: Revenues ($bn), Growth (%), CAGR (%), 2009-2025
Table 7.1 SWOT Analysis of the Chinese Pharma Market, 2010

Figure 2.1 The Chinese Pharmaceutical Market: Revenues ($bn), 2009-2025
Figure 3.1 Sectors of the Chinese Pharmaceutical Market: Revenues ($bn), 2009
Figure 3.2 Sectors of the Chinese Pharmaceutical Market: Revenues ($bn), 2009-2025
Figure 3.3 Branded and Generic Sectors: Revenues ($bn), 2009
Figure 3.4 Branded and Generic Drugs: Revenues ($bn), 2009-2025
Figure 3.5 Branded and Generic Drugs: Market Shares (%), 2009-2025
Figure 3.6 Medical Equipment Market: Revenues ($bn), 2009-2025
Figure 4.1 Prescription Drugs: Revenues ($bn), 2009-2025
Figure 4.2 Antibiotics: Revenues ($bn), 2009-2025
Figure 4.3 TCM: Revenues ($bn), 2009-2025
Figure 4.4 Vasotherapeutics: Revenues ($bn), 2009-2025
Figure 4.5 Solutions: Revenues ($bn), 2009-2025
Figure 4.6 Antiulcerants: Revenues ($bn), 2009-2025
Figure 4.7 Immunostimulating Agents: Revenues ($bn), 2009-2025
Figure 4.8 Diabetes Treatments: Revenues ($bn), 2009-2025
Figure 4.9 Vaccines: Revenues ($bn), 2009-2025
Figure 5.1 OTC Market: Revenues ($bn), 2009-2025
Figure 6.1 Clinical Trials Market: Revenues ($bn), 2009-2025
Figure 6.2 API Export Market: Revenues ($bn), 2009-2025
[Tabellenverzeichnis ausblenden]